Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

India Globalization Capital Inc (NY: IGC )

0.4390 -0.0176 (-3.85%)
Official Closing Price Updated: 4:10 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 428,784
Open 0.4626
Bid (Size) 0.4300 (3)
Ask (Size) 0.4490 (10)
Prev. Close 0.4566
Today's Range 0.4130 - 0.4688
52wk Range 0.2501 - 0.9099
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Shares Positive Interim Results on IGC-AD1 for Agitation in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence Cannabis
Exposures Artificial Intelligence Cannabis

Performance

YTD
+59.06%
+59.06%
1 Month
+9.75%
+9.75%
3 Month
+65.54%
+65.54%
6 Month
+39.37%
+39.37%
1 Year
+31.01%
+31.01%

More News

Read More
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
Via Benzinga
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
From IGC Pharma, Inc.
Via Business Wire
Who's Who In Cannabis: Latest Executive Changes You Should Know About
Via Benzinga
BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Adds AI Expert to Support Development of Phase 2 Clinical Trial
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Adds Advisor in Artificial Intelligence
From IGC Pharma, Inc.
Via Business Wire
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
Via News Direct
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
Via Benzinga
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Enters into $3M SPA with Leading Asset Management Company
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
From IGC Pharma Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Interim Results from Phase 2 Study Evaluating Treatment to Reduce Alzheimer’s Agitation
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
Via Benzinga
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
Via Benzinga
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Benzinga Virtual Healthcare Summit 2024
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
From IGC Pharma, Inc.
Via Business Wire
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
From IGC Pharma, Inc.
Via Business Wire
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
Via Benzinga
IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1
Via News Direct
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Names Healthcare Leader to Board of Directors
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
From IGC Pharma, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports ‘Promising’ Results in Preclinical Studies Evaluating Drug Candidate for Alzheimer’s Treatment
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Spotlighted in Ascendiant Equity Analyst Report
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.